Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06650761
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-18
Brief Title:
A Phase I Study of CDX-622
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Two-Part Phase 1a Dose Escalation Clinical Trial to Assess the Safety Pharmacokinetics and Pharmacodynamics of CDX-622 in Healthy Participants
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to determine the safety of CDX-622 in healthy participants
Detailed Description:
CDX-622 is a bispecific antibody that binds to stem cell factor SCF and thymic stromal lymphopoietin TSLP
This study will evaluate the safety pharmacokinetics and pharmacodynamics of CDX-622 in healthy participants
This study will evaluate the safety pharmacokinetics and pharmacodynamics of CDX-622 in healthy participants
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None